Death Domain Receptor Signaling Adaptor Proteins
"Death Domain Receptor Signaling Adaptor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Intracellular signaling adaptor proteins that contain DEATH EFFECTOR DOMAINS and bind to the cytoplasmic DEATH DOMAIN region found on DEATH DOMAIN RECEPTORS. Many of the proteins in this class take part in intracellular signaling involving TUMOR NECROSIS FACTOR RECEPTORS.
| Descriptor ID |
D053418
|
| MeSH Number(s) |
D12.644.360.024.285 D12.644.360.075.421 D12.776.157.057.018 D12.776.476.024.320 D12.776.476.075.421
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Death Domain Receptor Signaling Adaptor Proteins".
Below are MeSH descriptors whose meaning is more specific than "Death Domain Receptor Signaling Adaptor Proteins".
This graph shows the total number of publications written about "Death Domain Receptor Signaling Adaptor Proteins" by people in this website by year, and whether "Death Domain Receptor Signaling Adaptor Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Death Domain Receptor Signaling Adaptor Proteins" by people in Profiles.
-
Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res. 2010 May; 8(5):729-38.
-
Valmiki MG, Ramos JW. Death effector domain-containing proteins. Cell Mol Life Sci. 2009 Mar; 66(5):814-30.
-
Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther. 2008 May; 7(5):1156-63.